These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

714 related items for PubMed ID: 23010883

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
    Genant HK, Engelke K, Hanley DA, Brown JP, Omizo M, Bone HG, Kivitz AJ, Fuerst T, Wang H, Austin M, Libanati C.
    Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J.
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [Abstract] [Full Text] [Related]

  • 6. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis.
    Watts NB, Hattersley G, Fitzpatrick LA, Wang Y, Williams GC, Miller PD, Cosman F.
    Osteoporos Int; 2019 Jun; 30(6):1187-1194. PubMed ID: 30899994
    [Abstract] [Full Text] [Related]

  • 7. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC.
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [Abstract] [Full Text] [Related]

  • 8. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C.
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [Abstract] [Full Text] [Related]

  • 9. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study.
    Bolognese MA, Teglbjærg CS, Zanchetta JR, Lippuner K, McClung MR, Brandi ML, Høiseth A, Lakatos P, Moffett AH, Lorenc RS, Wang A, Libanati C.
    J Clin Densitom; 2013 Oct; 16(2):147-53. PubMed ID: 22521543
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM, Iranikhah MM, Wilborn TW.
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
    Nakamura T, Matsumoto T, Sugimoto T, Shiraki M.
    Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.